Navigation Links
Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
Date:9/24/2007

PITTSBURGH, Sept. 24 /PRNewswire/ -- Knopp Neurosciences Inc. ("Knopp") today announced the initiation of a Phase 1 clinical trial of KNS-760704, a small molecule therapy in development for the treatment of amyotrophic lateral sclerosis (ALS).

(Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO )

This randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers is being closely followed by a multiple ascending dose study in healthy subjects. Both studies are designed to evaluate the safety, tolerability and pharmacokinetics of KNS-760704 in human subjects.

"The initiation of Phase 1 represents a significant milestone in Knopp's efforts to develop a safe and effective therapy for a serious unmet medical need," said Michael Bozik, M.D., president and chief executive officer of Knopp. "We look forward to completing these safety studies and moving rapidly to advance the compound into initial clinical trials in ALS patients."

About KNS-760704

KNS-760704 is an orally administered small molecule in clinical development by Knopp for the treatment of amyotrophic lateral sclerosis (ALS). The drug is an optical enantiomer of a selective, high affinity dopamine agonist marketed in other neurological indications. Both KNS-760704 and the marketed agonist demonstrate neuroprotective properties independent of dopamine receptor activity, but KNS-760704 exhibits greatly reduced dopamine receptor affinity. This makes it possible to clinically evaluate the potential neuroprotective activity of KNS-760704 over a broad dose range.

About ALS

Amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease, is a rapid, universally fatal neurodegenerative disorder characterized by progressive muscle weakness and wasting. ALS affects adults in the prime of life and creates a substantial burden for caregivers. U.
'/>"/>

SOURCE Knopp Neurosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Generex Biotechnology Corporation ... of a white paper on the status of Generex ... white paper was presented to the August 19, 2015 ... James H. Anderson, Jr. , MD, the Company,s Chief ... on the Generex website. The white paper ...
(Date:8/27/2015)... -- Mytrus, a technology and services company revolutionizing clinical trials, announced today ... received approval for use by Britain,s ... time e-Consent technology will be used in a trial ... Mytrus was also the first electronic informed consent technology ... U.S. Food and Drug Administration in 2011. It has ...
(Date:8/27/2015)... The Elekta Linac-based Brain Stereotactic Radiation Therapy ... on July 9th for its inaugural meeting. Elekta created ... the potential of advances in linear accelerator technologies as ... an established provider of sophisticated cancer management systems worldwide, ... - in collaboration with its clinical partners - to ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3
(Date:8/27/2015)... ... 2015 , ... This new webinar educates providers about how can they create ... next visit, their authorizations are in check, and they are current with their payments. ... for Genesis Chiropractic Software, growing a practice depends on patient experience and clinician’s relationship ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... annual cost to treat a patient with hemophilia is $175,000. Hemophilia is an ... cure and improving treatment. The RMHBDA exists to help raise funds for patients ...
(Date:8/27/2015)... ... ... Thriveology Founders, Dr. Carly Letzt Carney and Dr. Mark Carney announced today ... Colorado on Saturday, August 29, 2015 at the Marriott DTC, 4900 S. Syracuse Street, ... and will present a two part seminar entitled, “How to Thrive as You Age ...
(Date:8/27/2015)... WILMINGTON, Del. (PRWEB) , ... August 27, 2015 , ... ... Hospital, will be the guest speaker at CURE® magazine’s 3rd Annual MPN Heroes™ ... , Dr. Arnold will be among hundreds of attendees honoring eight heroes who have ...
(Date:8/27/2015)... ... August 27, 2015 , ... Zensah®, the premium athletic compression ... for Israel in the Women’s Tennis Association (WTA). Glushko competes in tennis tournaments ... , With a focus on technology and comfort, Zensah® has developed compression gear ...
Breaking Medicine News(10 mins):Health News:A New Webinar Teaches Chiropractors How to Use Compliance Alerts to Manage Patient Relationships 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 4Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3
... Public Health has found that the state level rates of suicide ... ownership of firearm. ,"We found that where there ... Professor of Health Policy and Management at HSPH and lead author ... 15 leading causes of death in the U.S.; among persons less ...
... The Texas Youth Commission’s (TYC) facilities continue to reel under ... News unearthed sordid// details about the agency. , ... physical abuse of the juvenile inmates, as well as gross ... that the inmates have had to wait up to even ...
... sheer torture for your aching back too. If medication ... relief. ,Inserting fine needles into the skin ... and even moderately severe depression. ,"Acupuncture helps ... as migraines and arthrosis, but also stress and asthma," ...
... may no longer be a mantra to stay fit. ... effects// on human lifespan. ,Researchers at the ... into the benefits of commonly used vitamin supplements, including ... ,They found that vitamin supplements appeared to ...
... for head injuries at the Army Hospital at Delhi is ... a road accident in West Bengal on Saturday and is ... ,A team of top-notch specialists reviewed the minister's health in ... ,"He is able to walk around and is progressing ...
... to grips with global warming and climate change, the small ... way ahead. ,Bhutan is set to become the ... a constitutional obligation to preserve the environment, according to the ... from 24 nations of Asia gather in the Bhutanese capital ...
Cached Medicine News:Health News:Household Guns Associated With Higher Rates of Suicide in US 2Health News:Acupuncture Points Way to Relief from Many Ailments 2Health News:Recovering Pranab Mukherjee Likely to Be Discharged Tomorrow 2Health News:Bhutan Leads the World in Preserving the Environment 2
... Medpor Channel Implants, designed to ... the surgeon with an excellent ... wall and floor blowout defects. ... for placement of one or ...
The new Medpor Superior Lateral Orbital Rim is designed for subtle augmentation of the lateral and superior or orbital rims in patients who are hypoplasic in the superior-lateral aspect of the orbita...
The new Medpor Orbital Rim Onlay Implants are designed to support the lower eyelid and lateral canthus in patients who have inadequate support due to congenital variation or changes with aging....
... handle. Divides nucleus for phacoemulsification. Nuclear division ... hardness can be pre-chopped with pre-chop forceps ... fragments is rapid. Risk of rupturing posterior ... sound time and minimal movement of phaco ...
Medicine Products: